• Most Popular
  • Most Shared

Reuters Showcase

India Web Probe

India Web Probe

India investigates Google, Yahoo for possible forex violation: report  Full Article 

Delhi Israel Attack

Delhi Israel Attack

EXCLUSIVE: Attack on Israeli may hurt Indian trade with Iran - official.  Full Article 

Pakistan PM In Court

Pakistan PM In Court

Pakistan Supreme Court takes centre stage as political player  Full Article 

India Web Censorship

India Web Censorship

Sibal says no censorship on social media.  Full Article 

Syria Unrest

Syria Unrest

Latest from the ongoing crisis in Syria.  Full Article 

Growth in Online Love

Growth in Online Love

Plenty find love on the web, where lies abound - poll.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Philips develops "intelligent pill"

Related Topics

AMSTERDAM | Tue Nov 11, 2008 10:00pm IST

AMSTERDAM (Reuters) - Dutch group Philips has developed an "intelligent pill" that contains a microprocessor, battery, wireless radio, pump and a drug reservoir to release medication in a specific area in the body.

Philips, one of the world's biggest hospital equipment makers, said on Tuesday that the "iPill" capsule, measures acidity with a sensor to determine its location in the gut, and can then release drugs where they are needed.

Delivering drugs to treat digestive tract disorders such as Crohn's disease directly to the location of the disease means doses can be lower, reducing side effects, Philips said.

While capsules containing miniature cameras are already used as diagnostic tools, those lack the ability to deliver drugs, Philips said.

The "iPill" can also measure the local temperature and report it wirelessly to an external receiver.

The company plans to present the "iPill" at the annual meeting of the American Association of Pharmaceutical Scientists (AAPS) in Atlanta this month.

The iPill is a prototype but suitable for serial manufacturing, Philips said.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.